// App-Quantinova.ai

4580 : Interim results from a multicenter clinical study of tislelizumab combined with gemcitabine and cisplatin as neoadjuvant therapy for patients with cT2-T4aN0M0 MIBC.

Researchers

Presenter

  • Tianxin Lin

Principal Investigators

  • Kaiwen Li

  • Jinhai Fan

  • Shaogang Wang

  • Dexin Yu

  • Tao Xu

  • Jiaju Lyu

  • Kaijie Wu

  • Zheng Liu

  • Zhiquan Hu

  • Fan Li

  • Liangkuan Bi

  • Zhiqiang Zhang

  • Luping Yu

  • Sentai Ding

  • Jian Huang

Medical Centers

  • Department of Oncology, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou, China

  • Department of Oncology, the Second Affiliated Hospital of Nanchang University, Nanchang, China

  • Tongji Hospital of Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China

  • Department of Pediatrics, The Second Hospital of Anhui Medical University, Hefei, China

  • Department of Pathology, Peking University Peoples Hospital, Beijing, China

  • Department of Hematology, Shandong Provincial Hospital affiliated to Shandong University, Jinan, China

Locations

  • China

Companies

  • N/A

Study Components

Therapeutic Area

  • N/A

Disease

  • N/A

Biomarkers

  • N/A

Drug/Treatment

  • Tislelizumab

  • Gemcitabine

  • Cisplatin

Outcome

  • N/A

Study Design

  • Open Label

  • Single Arm

  • Multicenteric

Phase

  • II

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved